PairX Bio Pte Ltd is developing next generation cancer immunotherapies targeting shared tumor-associated antigens derived from aberrantly spliced proteins. The PairX platform is built upon a deep understanding of mRNA splicing biology, which when combined with our proprietary antigen and T Cell validation methods yield simultaneous validation of tumor antigen-T Cell pairs in multiple patient derived tumors. The foundational technology was developed at Duke-NUS Medical School in Prof. David Epstein’s lab (Founder & CEO of Black Diamond Therapeutics). The company was incubated by EVX Ventures and spun out from Duke-NUS. The founding investors are EVX Ventures and Avendesora (an investment company represented by Jeffrey Lu and Dr. Timothy Lu). For more information, visit https://www.pairxbio.com